LSE:GSKPharmaceuticals
GSK Refocuses R&D As WVE-006 Exit Sparks Valuation Questions
GSK (LSE:GSK) has returned rights to RNA editing therapy WVE-006 for alpha-1 antitrypsin deficiency to Wave Life Sciences.
The company is concentrating research on broader indications and scaling back rare disease efforts.
As part of this shift under new CEO Luke Miels, GSK is cutting 350 roles in its R&D organization.
GSK is a major global biopharma player with a focus on vaccines and specialty medicines, so any change in its R&D mix tends to matter for how its future portfolio could look...